Tazarotene topical Side Effects

Some side effects of tazarotene topical may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to tazarotene topical: topical cream, topical foam, topical gel/jelly

Along with its needed effects, tazarotene topical may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tazarotene topical:

More common
  • Burning or stinging of the skin (severe)
  • changes in color of the treated skin
  • deep grooves or lines in the skin
  • dryness, itching, peeling, or redness of the skin (severe)
  • pain or swelling of the treated skin
  • skin rash (in patients with psoriasis only)

Some side effects of tazarotene topical may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Burning or stinging after application
  • dryness, itching, peeling, or redness of the skin (mild)

For Healthcare Professionals

Applies to tazarotene topical: topical cream, topical foam, topical gel

Dermatologic

Dermatologic side effects associated with Avage(R) topical cream have included desquamation (40%), erythema (34%), burning sensation (26%), dry skin (16%), skin irritation (10%), pruritus (10%), irritant contact dermatitis (8%), stinging (3%), acne (3%), rash (3%), and cheilitis (1%). Pruritus, erythema, and burning have been reported (in descending order) with Tazorac(R) topical cream in 10% to 23% of psoriasis patients. Desquamation, dry skin, erythema, and burning sensation have been reported (in descending order) with Tazorac(R) topical cream in 10% to 30% of acne patients. Irritation, desquamation, stinging, contact dermatitis, dermatitis, eczema, worsening of psoriasis, skin pain, rash, dry skin, and skin inflammation have been reported (in descending order) with Tazorac(R) topical cream in greater than 1% to less than 10% of psoriasis patients. Pruritus, irritation, face pain, and stinging have been reported with Tazorac(R) topical cream in 1% to 5% of acne patients. Dermatitis (less than 1%), impetigo (less than 1%), pruritus (less than 1%), local skin reactions, dryness, erythema, peeling, burning/stinging, and itching have been reported with tazarotene topical foam. Pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, and skin pain have been reported (in descending order) with tazarotene topical gel in 10% to 30% of psoriasis patients. Desquamation, burning/stinging, dry skin, erythema, and pruritus have been reported (in descending order) with tazarotene topical gel in 10% to 30% of acne patients. Rash, desquamation, irritant contact dermatitis, skin inflammation, fissuring, bleeding, and dry skin have been reported with tazarotene topical gel in 1% to 10% of psoriasis patients. Irritation, skin pain, fissuring, and skin discoloration have been reported with tazarotene topical gel in 1% to 10% of acne patients. Psoriasis worsening and sun-induced erythema have also been reported with tazarotene topical gel in psoriasis patients. Blister, rash, skin discoloration (including skin hyperpigmentation or skin hypopigmentation), and pain have been reported during postmarketing experience with tazarotene topical gel.

Local

Local side effects associated with tazarotene topical foam have included application site irritation (14%), application site dryness (7%), application site erythema (6%), application site exfoliation (6%), application site pain (1%), application site photosensitivity (including sunburn; 1%), application site pruritus (1%), application site dermatitis (1%), and application site reactions (including discoloration, discomfort, edema, rash, and swelling; less than 1%). Localized edema has been reported with tazarotene topical gel in 1% to 10% of acne patients.

Metabolic

Metabolic side effects associated with Tazorac(R) topical cream have included hypertriglyceridemia (greater than 1% to less than 10%).

Other

Other side effects associated with Tazorac(R) topical cream have included peripheral edema (greater than 1% to less than 10%).

Ocular

Ocular side effects associated with Avage(R) topical cream have included edema, irritation, and inflammation directly related to the eye or eyelid.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)